KayoThera, Inc.

About KayoThera, Inc.

Kayothera is a preclinical-stage therapeutics company focused on pioneering first-in-class antagonists of the retinoid nuclear receptor pathway to address unmet medical needs in cardiometabolic diseases and cancer. Their mission is to develop innovative, safe, and effective therapies for conditions such as diabetes and obesity.

Products & Services

KAYO-1732:A first-in-class, oral inhibitor of the retinoid nuclear receptor pathway targeting Type 2 Diabetes and cardiometabolic indications.

KAYO-1609:A first-in-class, oral inhibitor of the retinoid pathway for genetically defined oncology indications, with plans to file an IND application by the end of 2024.

Retinoid Nuclear Receptor Pathway Inhibitors:Novel, orally-available small molecules that block the formation of retinoid or rexinoid nuclear ligands, aimed at managing diabetes, obesity, and other unmet medical needs.

Specialties

Retinoid Nuclear Receptor Pathway Inhibition Rexinoid Nuclear Receptor Pathway Inhibition Cardiometabolic Disease Treatment Cancer Treatment Small Molecule Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 5200000 MR: - FA: 5.2 million FAN: 5200000	D: 2023-07-19 FD: 2023-07-19	4 investors

Series A Latest

2023-07-19

$5.2M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

THONG Q. LE

President and CEO and Board Member

I

IAN HOWES

Chief Financial Officer

M

MARK ESPOSITO

CSO, Co-Founder and Board Member

M

MERIKA KODAY

Board Member

B

BRUCE CARTER, PH.D.

Chairman and Board Member

P

PAUL SEKHRI

Board Member

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

KayoThera, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised